Aminocaproic Acid Injection 250 mg /mL Multiple-Dose Vial 20 mL x 25/Tray (RX)

Aminocaproic Acid Injection is used to prevent and treat excessive bleeding in conditions with high fibrinolysis, such as during surgery or trauma. It works by inhibiting plasminogen activators, stabilizing blood clots and minimizing bleeding risk. Commonly utilized in hematologic disorders, it supports hemostasis and promotes efficient post-operative recovery. By controlling hemorrhagic episodes, this medication is crucial for patients needing rapid intervention to prevent excessive blood loss and ensure optimal healing.

American Regent's Aminocaproic Acid Injection offers a trusted solution in the management of acute bleeding episodes. This antifibrinolytic agent, presented in a multiple-dose vial, is designed for flexibility and efficiency in various clinical settings. By stabilizing clot integrity, aminocaproic acid plays a crucial role in controlling excessive bleeding and ensuring patient safety during surgical and trauma interventions.

Product Details and Features:

• Active Ingredient: Aminocaproic Acid, an effective antifibrinolytic agent.
  
• Concentration: Each milliliter contains 250 mg of aminocaproic acid.
  
• Volume: Provided in a 20 mL vial, available in a tray of 25 for institutional use.
  
• Formulation: Clear, sterile solution ensuring ease of administration.
  
• Manufacturer: American Regent, renowned for quality and reliability in pharmaceutical products.
  
• Primary Use: Supports hemostasis by reducing excessive bleeding in clinical settings such as surgeries and bleeding disorders.

Mechanism of Action:

Aminocaproic Acid works by inhibiting fibrinolysis, the enzymatic breakdown of fibrin in blood clots. It achieves this by blocking the binding sites of plasminogen and plasmin to fibrin, effectively preventing the dissolution of fibrin clots. This action helps maintain hemostatic plugs and stabilizes clot formation, reducing bleeding during surgical procedures and in conditions with hyperfibrinolysis.

Directions for Use:

Administration:

• Aminocaproic Acid Injection is administered intravenously.
  
• Dosage depends on the patient's condition and medical guidance. Typical dosing may initiate with 4-5 g over a 1-hour span, followed by a sustaining infusion.

2. Dilution and Infusion:

• The solution should be diluted with a compatible intravenous fluid before administration.
  
• Administer as a continuous or intermittent infusion considering the clinical scenario.

3. Monitoring:

• Monitor fibrinolytic activity and patient response during treatment.
  
• Adjust dosing based on blood loss and clinical outcomes.

Warnings:

• Hypersensitivity: Avoid in patients with known hypersensitivity to aminocaproic acid or any formulation component.
  
• Renal Impairment: Cautious use is required in patients with renal insufficiency, monitoring for possible accumulation.
  
• Thromboembolic Risk: Elevated thromboembolic risk in certain patients necessitates a clinical risk-benefit analysis.
  
• Intravenous Compatibility: Ensure compatibility of infusion fluids; avoid using solutions with precipitates.

Side Effects:

• Common: Nausea, vomiting, diarrhea, headache, or dizziness may occur.
  
• Serious: Rarely, it may precipitate thrombosis, renal failure, or cause muscle weakness.
  
• Allergic Reactions: Monitor for signs like rash, itching, severe dizziness, or trouble breathing, and manage promptly.

American Regent's Aminocaproic Acid Injection remains a vital tool in the clinical arsenal to achieve effective and targeted control over bleeding complications. Always rely on health professional guidance to navigate dosage adjustments and therapeutic integration tailored to individual patient needs and clinical conditions.